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Autoantibodies against Type I Interferons as an
Additional Diagnostic Criterion for Autoimmune
Polyendocrine Syndrome Type I
Antonella Meloni,* Maria Furcas, Filomena Cetani,* Claudio Marcocci, Alberto Falorni,*
Roberto Perniola,* Mikula´sˇ Pura,* Anette S. Bøe Wolff, Eystein S. Husebye, Desa Lilic,*
Kelli R. Ryan, Andrew R. Gennery, Andrew J. Cant, Mario Abinun, Gavin P. Spickett,
Peter D. Arkwright, David Denning, Colm Costigan, Maria Dominguez, Vivienne McConnell,
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Context: In autoimmune polyendocrinopathy syndrome type I (APS-I), mutations in the
autoimmune regulator gene (AIRE) impair thymic self-tolerance induction in developing T cells.
The ensuing autoimmunity particularly targets ectodermal and endocrine tissues, but chronic
candidiasis usually comes first. We recently reported apparently APS-I-specific high-titer neu-
tralizing autoantibodies against type I interferons in 100% of Finnish and Norwegian patients,
mainly with two prevalent AIRE truncations.
Objectives:Becausevariability inclinical featuresandageatonset inAPS-I frequentlyresults inunusual
presentations, we prospectively checked the diagnostic potential of anti-interferon antibodies in
additional APS-I panelswith other truncations or raremissensemutations and in disease controlswith
chronic mucocutaneous candidiasis (CMC) but without either common AIREmutation.
Design: The study was designed to detect autoantibodies against interferon-2 and interferon-
in antiviral neutralization assays.
Setting and Patients: Patients included 14 British/Irish, 15 Sardinian, and 10 Southern ItalianAIRE-
mutant patients with APS-I; also 19 other patients with CMC, including four families with coseg-
regating thyroid autoimmunity.
Outcome: The diagnostic value of anti-interferon autoantibodies was assessed.
Results:We found antibodies against interferon-2 and/or interferon- in all 39 APS-I patients vs.
zero of 48 unaffected relatives and zero of 19 British/Irish CMC patients. Especially against inter-
feron-, titers were nearly always high, regardless of the exact APS-I phenotype/duration or AIRE
genotype, including 12 different AIRE length variants or 10 point substitutions overall (n  174
total). Strikingly, in one familywith few typical APS-I features, these antibodies cosegregated over
three generations with autoimmune hypothyroidism plus a dominant-negative G228W AIRE
substitution.
Conclusions: Otherwise restricted to patients with thymoma and/or myasthenia gravis, these
precocious persistent antibodies show 98% or higher sensitivity and APS-I specificity and are
thus a simpler diagnostic option than detecting AIRE mutations. (J Clin Endocrinol Metab 93:
4389–4397, 2008)
0021-972X/08/$15.00/0
Printed in U.S.A.
Copyright © 2008 by The Endocrine Society
doi: 10.1210/jc.2008-0935 Received April 30, 2008. Accepted August 20, 2008.
First Published Online August 26, 2008
* A.M., F.C., A.F., R.P., M.P., and D. L. contributed equally to this study.
** Author affiliations are shown at the bottom of page 2
Abbreviations: AD, Addison’s disease; AIRE, autoimmune regulator; APECED, autoimmune
polyendocrinopathy candidiasis ectodermal dystrophy; APS-I, autoimmune polyendocrine
syndrome type I; AVINA, antiviral neutralization assay; CARD, caspase recruitment domain;
CC, chronic Candida infections; CMC, chronic mucocutaneous candidiasis; hAT, autoim-
mune hypothyroidism; HP, hypoparathyroidism; IFN, interferon; MG, myasthenia gravis;
OMIM, Online Mendelian Inheritance in Man; SLE, systemic lupus erythematosus.
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Studies on monogenic autoimmune diseases have greatlyincreased our understanding of normal mechanisms of
self-tolerance and of its breakdown (1–4). For example, the
autoimmune polyendocrine syndrome type I APS-I: Online
Mendelian Inheritance in Man (OMIM) 240300 is caused by
autosomal (mostly recessive) mutations in the autoimmune reg-
ulator gene (AIRE) (3, 4). This highly interactive transcriptional
regulator (see Fig. 1) normally governs the expression in thymic
medullary epithelial cells of peripheral tissue-restricted antigens
such as insulin (5); these delete potentially autoaggressive nas-
cent T cells (2, 6, 7) and apparently select specific regulatory T
cells (8, 9).
Alsoknownasautoimmunepolyendocrinopathycandidiasisec-
todermaldystrophy (APECED),APS-I ismoreprevalent inFinnish,
Norwegian, Sardinian, and Iranian Jewish populations. Highly
variableclinically, genetically, andserologically, it typically starts in
the first or second decades with chronic cutaneous and/or mucosal
candidiasis (CC), followed by autoimmune hypoparathyroidism
(HP) and/ or adrenocortical failure Addison’s disease (AD) (1).
Probandswith any twoof this triad (or relativeswith just one)meet
current criteria for diagnosis of APS-I. Frequent additional targets
may be ectodermal (skin, nails, and teeth), endodermal (stomach,
liver, and intestines), gonadal, and sometimes other endocrine
glands such as the thyroid or, especially in Finland (1), the pancre-
atic islets. The well known autoantibodies, often to intracellular
enzymes, co-occur mainly with autoimmunity against specific tar-
get organs (1, 10–12) and are not general/early markers for APS-I
(12).
Increasingly, patients with prodromal APS-I or with less typ-
ical presentations are also proving to have AIRE mutations (1,
13–15).However, their detection can be time consuming, costly,
locally unavailable, or occasionally unsuccessful, even in appar-
ently typical patients (1). Surprisingly, we find high-titer neu-
tralizing autoantibodies against interferon (IFN)- (usually all
its 12 molecularly distinct subtypes), and especially the approx-
imately 60% identical IFN-, in 100% of Finnish and Norwe-
gian APS-I patients with (mostly truncating) mutations detected
in both AIRE alleles and even in some where they have not (yet)
been found (16).
These antibodies seem highly specific for APS-I. Otherwise,
we find them only in patients with myasthenia gravis (MG) or
thymoma (20–30%) or both together (70%), but not in nu-
merous other autoimmune, infectious, or neoplastic diseases
(17) (see Table 3). Titers inAPS-I are almost always high initially
and persist for decades thereafter, so they obviously have po-
tential diagnostic value. So far, however, we have systematically
tested only Nordic patients with large truncations of the 545-
amino-acid AIRE protein e.g. R257X in Finland; p.C322
fsX372 (c.967/979del13) in Norway, although about 50 other
mutations have now been reported in AIRE (3, 4, 7, 18–25).
Pathogenic mutations are located along its length (Fig. 1), but
they show few phenotypic correlations.
We have now tested 39 additional patients with different
truncations (from the United Kingdom, Ireland, and central
Sardinia) (18) or rare point substitutions (from Apulia in the
heel of Southern Italy) (20) plus six from the unique family 1
(from central Italy) (22) who presented mainly with autoim-
mune hypothyroidism (hAT; see Fig. 2) and a dominant-neg-
ative G228W substitution (23).
Despite their early onset and high prevalence in APS-I, the
chronic Candida infections remain unexplained. Chronic
mucocutaneous candidiasis (CMC) can instead occur sporadi-
cally or in families (i.e. without AIRE mutations), but its diag-
nosis is purely clinical; no genetic or biochemical markers are
currently available. However, in some families, it shows auto-
somal dominant (OMIM 11458) or recessive OMIM 212050)
inheritance, sometimes cosegregating with thyroid autoimmu-
nity (27). We have tested 19 such patients for anti-IFN antibod-
ies, partly in case they have undetected mutations in AIRE, its
partners, or targets and partly as additional disease controls.
Here we show that, despite many differences in both clinical
phenotypes and AIRE genotypes, the anti-IFN antibodies are
remarkably consistent. They correlate almost perfectly with
APS-I disease, even now that we have tested more than 30% of
the approximately 500 patients reported worldwide (28), and
about 40% of their mutations.
Patients and Methods
Patients
With informed consent and ethics committee approval, we tested the
earliest available sera from four patient panels: 1) 15APS-I patients from
Sardinia (18) (disease durations10 yr); 2) 10 APS-I patients fromApu-
lia, Southern Italy (20) (durations10 yr); 3) six patients with atypical
APECED from family 1 (durations up to 32 yr) (22) (also four unaffected
relatives; see Fig. 2). Family 1 has recently been rescrutinized for para-
thyroid and adrenal function, gastric and islet cell autoantibodies and
candidiasis, and ectodermal dystrophies. A fourth group included 33
patients from a United Kingdom/Ireland study on candidiasis (Ryan,
K.R., and D. Lilic, submitted), including 14 with APECED plus AIRE
mutations and 19 with sporadic or familial CMC with or without hAT.
Because most of the unusual patients had presented years previously,
early samples were seldom available. The healthy controls included 21
age- and sex-matched children undergoing general anesthesia for non-
Pediatric Clinic II (A.Mel., M.F.), Ospedale Microcitemico and Dipartimento di Scienze Biomediche e Biotechno-logiche, University of Cagliari, 09121 Cagliari, Sardinia, Italy; Department
of Endocrinology and Metabolism (F.C., C.M.), University of Pisa, 56127 Pisa, Italy; Department of Internal Medicine and Endocrine and Metabolic Sciences (A.F.), University of Perugia,
06123 Perugia, Italy; Department of Paediatrics-Neonatal Intensive Care (R.P.), V. Fazzi Regional Hospital, 73100 Lecce, Italy; Department of Endocrinology (M.P.), National Institute of
Endocrinology and Diabetology, 03491 Lubochna, Slovakia; Section of Endocrinology (A.S.B.W.), Institute of Medicine, University of Bergen, and Department of Medicine (E.S.H.),
Haukeland University Hospital, N-5021 Bergen, Norway; Institute for Cellular Medicine (D.L., K.R.R.), Faculty of Medical Sciences, Newcastle University, and Departments of Paediatric
(A.R.G., A.J.C., M.A.) and Regional Immunology (G.P.S.), Newcastle-upon-Tyne Hospitals National Health Service Foundation Trust, Newcastle NE1 7RU, United Kingdom; Booth Hall
Children’s Hospital (P.D.A.) and Education and Research Centre (D.D.), Wythenshawe Hospital, University of Manchester, Manchester M23 9LT, United Kingdom; Our Lady’s Hospital
for Sick Children (C.C., M.D.), Dublin 12, Ireland; Northern Ireland Regional Genetics Service (V.M.), Belfast City Hospital Trust, BT9 7AB Belfast, Northern Ireland, United Kingdom;
Neuroscience Group (N.W.), Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; and Biotherapeutics Group (A.Mea.), National Institute
for Biological Standards and Control, Blanche Lane, South Mimms EN6 3QG, United Kingdom
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infectious conditions (e.g. for circumcisions or hernias) and 11 labora-
tory adults.
Antibody assays
The ELISA and antiviral neutralization (AVINA) assays have been
described (16, 17). In brief, for AVINA, dilutions of patient (or control)
sera were preincubated for 2 h with diluted IFN-2 (Hoffmann-La
Roche, Basel, Switzerland) or IFN- (Bender and Co., Vienna, Austria)
(10 U/ml). Human glioblastoma cells (line 2D9) (16) were added; after
an additional 24 h, they were challenged with encephalomyocarditis
virus for 24 h, washed, stained with 0.05% amido blue black, fixed, and
washedbefore absorbancewas read at 620nm.Apart from theApulians,
all sera were tested blind of their APS-I or relative status.
Results
Overall, the results in the present samples are remarkably clear
(summarized inTable 1 and supplemental Fig. A, published as sup-
plementaldataonTheEndocrineSociety’s JournalsOnlinewebsite
at http://jcem.endojournals.org).We found neutralizing antibodies
against IFN- in all 39APS-I patientswithmutations inbothAIRE
alleles and in all six patients in family 1 (see Fig. 2). Titers were at
least 1:4500 in all 31 Italians and at least 1:600 in the 13 from the
United Kingdom/Ireland; most were much higher (Table 2), up to
1:4 106 (16). They were also high against IFN-2 (1:3200) in
30 of the 31 Italians (with one exception aged 82 in family 1) and
in all 14 patients from the United Kingdom/Ireland (7000).
We detected no antibodies against either IFN-2 or IFN-
(1:60 background) in 48 unaffected Italian relatives (Table 2 and
supplemental Fig. A), in 68 new disease controls with either CMC
(supplemental Table A) or AD alone, or in numerous previous dis-
ease or healthy controls, numbering about 800 overall (Table 3).
Antibodies against IFN- were readily detected in the APS-I
patients, 1) whatever their exactAIREmutations, from position
8 to the stop codon (Table 1) or their (hetero)zygosity (supple-
mental Table B), and 2) in all the patients without the full APS-I
triad (Tables 2 and 3), indeed, regardless of their exact clinical
features or durations (up to 32 yr in patient III-1 in family 1;
details in supplemental Tables C and D).
Evidently, the anti-IFNantibodies are not an effect of any one
disease component or mutation. In our previous studies (15, 16,
25), they were also present from the earliest sampling time on-
ward; the single exceptional patient later became very strongly
positive (16). In every informative case, titers have remained
consistently high for up to about 30 yr (16). Moreover, 11 of 11
Finnish patients diagnosed clinically were antibody positive
when first tested (16) and subsequentlyproved tohavemutations
in both AIRE alleles (not shown). Thus, these antibodies seem
highlydisease-specific andmusthave significantdiagnostic value
(see below and Table 3).
FIG. 1. The AIRE mutations tested and the domains and actions they affect. The point substitutions so far tested are shown in red: M and m, tested in dominant/
homo- or heterozygous states, respectively. The length variants are in blue; premature stops often follow an intervening frameshift (fsX). LXXLL, Nuclear receptor-
binding motifs; Lz, Leu zipper; NLS, nuclear localization signal; PHD, plant homeodomain (Zn finger-containing protein-protein interactive domains found in many
transcriptional regulators); PRR, proline-rich region (found in many proteins that regulate transcription at the chromatin level); PXXPXP, important for transactivation;
SAND, Sp100, AIRE, Nuc p41/75, DEAF domain, potentially DNA-binding. CARD (26) overlaps the homogeneously staining region and is thought to be crucial for AIRE
homodimerization. Additional references on AIRE domains are given at the end of the supplemental data.
FIG. 2. Family 1 pedigree. III-1 is the proband. Half-black circles and squares
indicate females or males with AIRE G228W mutation plus hAT (plus anti-thyroid
peroxidase antibodies), which was the only manifestation in three of them. The
numbers below indicate anti-IFN titers (103). †, This aunt had severe
hypocalcemia in childhood and died suddenly at age 40 (22).
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Do anti-IFN antibodies show any correlations with
clinical features?
With autoimmune features of APS-I
Notably, antibodies against IFN-were clearly present in all
the less typical patients, even in the 20 of 44with only one or two
of theAPS-I triad (Tables 2 and3 and supplemental TablesCand
D). Indeed, titers did not correlate clearly with the numbers or
durations of APS-I features.
Both the anti-IFN antibodies and themain clinical features in
the newly tested APS-I patients appear broadly similar to those
in Nordic series reported previously (supplemental Table D).
However, hATmay be less frequent in the latter. It was reported
in only about 10% of Norwegians (15) and only about 30% of
Finnswith APS-I (usually as a late sign) (1), whereas it was noted
here in four of the 10 Southern Italians. It was also the one
disorder common to all the six patients tested in family 1, only
one of whom developed AD, after a 25-yr delay, and eventually,
therefore, the full APS-I triad (Table 2 and Fig. 2). Nevertheless,
all six had antibodies against IFN- (and five also against IFN-
2); these showed no clear differences in the three with CC
and/or HP and the three without.
With candidiasis
All of our14newBritish and IrishAPS-I patientswithCCplus
R257X and/or p.C322fsX372 mutations were strongly positive
for anti-IFN antibodies (Table 2). Remarkably, so were all the
13 rare APS-I patients either without CC at their last assess-
ment (n  11) or whose CC began only in adulthood (n  2)
(supplemental Table A). They include five of the present Ital-
ian patients (four from family 1; Fig. 2) and several others
reported recently (15, 25). Although titers were strongly pos-
itive against IFN- inallof them, theywere lowornegativeagainst
IFN-2 in five of the 13 but high in the other eight (supplemental
Table A).
Do anti-IFN antibodies show any correlations with AIRE
mutations?
AIRE truncations/extensions
In fact,we foundantibodies against IFN-2and IFN- in all the
34 newly tested patients with three different AIRE truncations
(Table 2 and supplemental Table B). These included the Sardinians
with the short R139X, even one with only one mutation detected
(supplemental Table B). More surprisingly, titers were also high in
the patientswith theV22-D23mini-deletion (lower Table 2) or the
TABLE 1. Summary of anti-IFN antibodies and AIRE mutations in APS-I patients
AIRE mutations Ref. n
Neutralizing antibodies against
IFN-2 IFN-
Truncations/extensions
R139X hom 12  or –  or 
R139X/not detected 1  
R257X hom 15, 16 57 54  ; 3a – 56  ; 1a –
C322fsX372 hom 15 10  to – 100%  
p.IVS7  1G3A,b hom 15 2  or – 
C311fsX376 hom 1  
R257X/H415fsX422 15 2  
L417fsX422 hom 15 1  
R257X/X546C  59 aa 15 4   to 
Totals 8/151c negative 1/151c negative initially
Missense mutations
R8C  S135Qd 1 – 
R8C  L97P 1  
W78R hom 3  
W78R  V22-D23del 1  
W78R  P252L 1  
W78R  Q358X 3  
Y85C hom 29 1  (ELISA) ND
R92W  truncations 25 2  to   to 
G228W  wt family 1 5  to   to 
Grandmother 1 – 
C311Y  R257X 2  or – 
C446G  R257X 1 – 
P539L hom 1  
Totals 5/23c negative 0/22c negative
–, 1:60; , 1:120; , 1:10,000; , 1:50,000. aa, Amino acids; hom, homozygous; ND, not done; wt, wild type.
a One initially negative patient was strongly positive against both IFNs in both subsequent bleeds (16).
b Also called c.879  1G3A.
c Totals include additional compound heterozygotes omitted here for clarity.
d Also called c.402delC.
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stop codonmutation/extension (supplementalTableD).Theywere
similar in nearly all the recently reported Nordic and U.S. cases,
again regardless of their APS-I durations (supplemental Table D).
Point substitutions
Titers were also high against both IFN-2 and IFN- in all
nine newly tested Southern Italian patients with missense muta-
tions (Table 2). In stark contrast, they were never above back-
ground inanyof the48heterozygous relatives testedhere (Tables
2 and 3).
This precise cooccurrence with APS-I disease is especially
striking in the (nonconsanguinous) family 1 (Fig. 2 and Table 2),
whose hAT is coinherited with the AIRE G228W mutation but
without the APS-I triad in six of the seven cases (22). The anti-
IFN antibodies show similar (dominant) cosegregation with
AIRE G228W over three generations, being clearly negative in
their four available unaffected relatives.
These findings are further supported by recent reports of
high-titer anti-IFN antibodies in: 1) two Slovaks with one
R92W plus one truncating AIRE mutation (25) but without
CC (supplemental Tables A and D), 2) one Y85C homozygote
(with the full APS-I triad) who was Iranian in origin (29), and
3) five Finnish or Norwegian patients with four other point
substitutions (supplemental Table D).
Diagnostic specificity and sensitivity
Table 3 summarizes our entire experience. We have now
found anti-IFN antibodies in all 174 APS-I patients tested, in-
cluding at least 47 without the full triad, two with only a single
AIREmutation detected, and another two with none found ini-
tially who later proved to be R257Xhomozygous (supplemental
TableB).Notably,we foundnoanti-IFNantibodies in three final
patients, each with just two of the APS-I triad and no AIRE
mutations detected; there are other serious doubts about their
APS-I diagnoses (supplemental Table B) (15, 16, 25).
In stark contrast, these antibodies were found in none of 58
unaffected relatives in total, noneof 84 single disease controls for
APS-I, none of 119 healthy subjects, and only one of 733 addi-
tional controls with other infectious, autoimmune, or neoplastic
diseases (Table 3). Even that one has systemic lupus erythema-
tosus (SLE), where IFN- is heavily implicated (31).
Therefore, apart from theirwell knownprevalence in patients
withMG and/or thymoma (16, 17), anti-IFN- antibodies seem
TABLE 2. Anti-IFN antibodies in newly tested APS-I patients with truncations or missense mutations in both AIRE alleles
AIRE mutation
APS-I triad/total
patients tested
Neutralizing antibodiesa
Anti-IFN-2 Anti-IFN-
No.
positive/total Titer  103
No.
positive/total Titer  103
Length variants
Sardinia
R139X hom 7/12 12/12 512–14 12/12 512–14
R139X/C322fsX372 1/2 2/2 500–5 2/2 256–180
Unaffected relativesb 0/33 All 	0.04 0/33 All 	0.04
Apulia
C311fsX376 hom 0/1 1/1 256 1/1 200
Unaffected relativesb 0/1 	0.04 0/1 	0.04
UK and Ireland
R257X and/or C322fsX372 8/14 14/14c 512–7 14/14c 512–0.6
Totals 16/29 29/29 29/29
Missense AIRE mutations
Apulia
W78R hom 2/3 3/3 256–64 3/3 135–25
W78R/P252 1/1 1/1 128 1/1 110
W78R/V22-D23del 0/1 1/1 256 1/1 110
W78R/Q358X 3/3 3/3 256–70 3/3 256–70
P539L hom 1/1 1/1 50 1/1 12
Unaffected relativesb 0/10 All 	0.04 0/10 All 	0.04
Rome family 1
G228W/wt 1/6 5/6 331–0.06 6/6 1024–4.5
Unaffected relatives 0/4 All 	0.04 0/4 All 	0.04
Totals 8/15 14/15 15/15
Grand totals 24/44 43/44 44/44
p.C322fsX372 is also called c.967–979del 13. wt, Wild type.
a The titers of anti-IFN antibodies are listed as the highest to lowest in each group.
b The unaffected relatives from Sardinia were all heterozygous for AIRE mutations; one Apulian was V22_D23del/wt heterozygous, and three were Q358X/wt (one with
non-autoimmune nodular hyperthyroidism).
c One 7-yr-old boy had similarly high titers despite having only CC (onset age 2 yr) of the triad.
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tightly restricted toAPS-I,where their sensitivity, specificity, and
predictive values exceed 98% (Table 3).
Technical caveats
Testing against IFN- and IFN-2
In the 174APS-I cases, we noted eight exceptionswhere titers
against IFN-2were scarcely above background in the first sam-
ple (Tables 2 and 3), although they rose subsequently in at least
two (16). Therefore, we favor also testing against IFN-, which
nearly always revealed substantial titers. The lowest noted here
were 1:1500 vs. IFN- and 1:200 vs. IFN-2 or 1:600 and
1:7000 (Table 2 and supplemental Fig. A). Overall, these two
antibodies correlated only modestly in the present samples
(r  0.41).
Binding vs. neutralizing assays
We have also tested 143 of the 174 APS-I samples by ELISA
against IFN-2 and 58 by RIA against in vitro translated IFN-
(43). In general, sera with high (or low) titers in one assay have
high (or low) titers in the other. However, a few exceptional
sera with moderate neutralizing titers (1:45,000) (especially
from MG patients) have given only weak ELISA signals
(20% saturating). These latter overlap with the values in
occasional control or postviral samples (Meager, A., unpub-
lished) (17).
With their consistently low backgrounds (1:120), neutral-
ization assays highlight the autoantibodies in APS-I or MG/thy-
moma patients more starkly than binding assays. Alternative
neutralization tests based on IFN-inducible proteins, e.g.MxA,
arenowavailable for theseautoantibodies (32,33); someof them
are simpler than AVINA. Such tests are sensitive, robust, and
straightforward and should be readily applicable in routine di-
agnostic laboratories. They are also quicker, simpler, and
cheaper andmay yield fewer false negatives (supplemental Table
B) than defining mutations in AIRE, among which many labo-
ratories screen only for the commoner ones.
TABLE 3. Neutralizing antibodies against IFN-2 and IFN- as diagnostic markers for APS-I; comparisons with disease and healthy
controls
Donor group
Patient numbers tested
This paper Previously (Ref.) Anti-IFN-2 Anti-IFN-
APS-I
APS-I total 45 123 (15, 16, 25) 166/174 173/174a
APS-I but without full APS-I triad 20 27 (15, 16, 25) 43/47 47/47
APS-I with 	2 AIRE mutations detected initially 1 6 (15, 16, 25) 4/7 4/7
Controls
Healthy controls 49 (supplemental Table A) 70 (17) 0/119 0/119
Unaffected APS-I relatives 48 (Table 2) 10 (16) 0/58 0/58
Subtotals 0/177 0/177
Disease controls
APS-2 27 9 (16, 25) 0/36 0/36
AD alone 49 11 (16, 25) 0/60 0/60
HP alone 2 (16) 0/2 0/2
CMC alone 
 hAT 19 (Supplemental Table A) 3 (16) 0/22 0/22
IDDM (17) 0/29 0/29
Thyroid autoimmunity (17) 0/25 0/25
Pemphigoid (17) 0/67 0/67
Di George syndrome 48 0/48 0/48
Neurological (17) 0/124 0/124
Neoplastic (17) 0/70 0/70
Postviral (17) 0/94 ND
Rheumatological
OA, giant cell arteritis, polymyalgia
rheumatica, RA
(30) 0/70 0/70
SLE 1/50b 0/50
Subtotals 1/695 0/601
Grand totals 1/874 0/780
Sensitivity 95.4%, 166/174a 99.4%, 173/174a
Specificity 99.9%, 873/874 100%, 780/780
Predictive values
Positive 99.4%, 166/167 100%,173/173
Negative 99.1%, 873/881 99.9%, 780/781
IDDM, Isulin-dependent diabetes mellitus; ND, not done; OA, osteoarthritis; RA, rheumatoid arthritis.
a In Ref. 16, just one AIRE-mutant patient (E) initially tested negative against both IFN-2 and IFN-, but she was strongly positive in both subsequent samples
(for unknown reasons). Because the present paper focuses on early diagnosis, we have classed her as negative because of her first sample.
b This patient had neutralizing titers (1/3,500 to 1/10,000) against IFN-2 in her first and later samples (over 13 yr). One other SLE patient had low titers against IFN-8
only (	1/1000) and was consistently negative against IFN-2 over about 10 yr. We never detected neutralizing antibodies against IFN- in any sample from either
patient.
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Discussion
We summarize here an almost perfect correlation between au-
toantibodies to IFN- and APS-I-type disease in a grand total of
174patientswith 12differentAIRE length variants and10point
substitutions scattered from position 8 to the stop codon. The
correlation applies equally to patients from different Italian re-
gions (with particularly heterogeneous mutations), Ireland and
United Kingdom (this report), Finland (16), Norway (15),
Slovakia (25), and the United States (29, 34). Together, these
represent around one third of all the cases, and nearly 40% of
the mutations, so far reported worldwide (28).
Anti-IFN antibodies as diagnostic markers
We foundneutralizing antibodies against IFN- in all the 174
APS-I patients we have tested, whether they had the full APS-I
triad or not and whatever their clinical phenotypes or AIRE
genotypes. We also found antibodies against IFN-2 in 166 of
them. Not only were they clearly positive at or near diagnosis
(with only one exception) (16), even at age 3.3 yr, but also in
every subsequent sample (up to 32 yr later).
Clearly, therefore, these antibodies are highly specific forAPS-I.
They are also much more omnipresent than any others so far re-
ported (10–12). These appear later, may be more transitory, cor-
relate more with the particular organs targeted, and so have lower
overall sensitivities (10–12).
We propose that the AVINA, a sensitive biological assay for
neutralizing anti-IFN antibodies, be considered a front-line di-
agnostic test for APS-I. These antibodies can be detected much
more simply, quickly, and cheaply than AIRE mutations (espe-
cially in regions where these are more heterogeneous than in
Finland) and apparently with fewer false negatives. Their great-
est practical value will probably be in identifying prodromal or
atypical cases (1, 13–15), which may pose significant clinical
challenges. Especially in children, e.g. presenting with isolated
CC, early diagnosis can alert physicians to the potential for fatal
HP demanding lifesaving monitoring and treatment.
We therefore propose that patients with just one of the APS-I
triad could be assigned a provisional diagnosis of APS-I if they
test positive for anti-IFN antibodies, subject to subsequent clin-
ical evolution and/or identification of AIRE mutations.
Thus, the initial criteria might be any two of: 1) CC, 2) HP,
3) AD, or 4) AIRE mutations or anti-IFN antibodies (Fig. 3).
Additionally, we recommend testing for these antibodies in
youngpatientswith other atypical presentations ofAPS-I such as
unexplained hepatitis, keratopathy, periodic rash with fever,
chronic diarrhea, severe obstipation, or pernicious anemia.
If such a definition is formally accepted, then one should
remember that these neutralizing antibodies are also common in
patients with late-onset MG (after age 40) and/or thymomas.
These disorders seem unlikely to be confused because: 1) they
are rare in childhood/adolescence, when APS-I usually pre-
sents, and 2) endocrine autoimmunity is rare in both, and so
is CMC. Otherwise, we have detected anti-IFN antibodies in
only one of more than 600 disease controls, with SLE (17).
Together with 161 healthy controls, these give a sensitivity
and specificity of more than 98% and equally high positive
and negative predictive values (Table 3).
There are two methodological caveats. Occasional APS-I
patients have high-titer neutralizing antibodies against IFN-
but not IFN-2 (or rarely vice versa), so optimal diagnostic tests
should include both types. Second, we strongly favor neutral-
ization assays, because of their consistently low backgrounds
and uniquely sensitive detection/quantification of functionally
relevant neutralizing antibodies that recognize correctly folded,
active IFNs. By contrast, although they may be invaluable for
newly cloned autoantigens that are not easily purified in bulk,
ELISAs andRIAs can also detect antibodies specific for unfolded
targets (12). ELISAs are also much more error prone; because of
their variable backgrounds and lower signal to noise ratios, they
can detect low levels of low-affinity binding (but nonneutralizing)
antibodies, e.g. after intercurrent infections (17).
Anti-IFN antibodies and Candida infections
Chronic infection is surprisingly uncommon inAPS-I, despite
the high levels of neutralizing anti-type I IFN antibodies. These
are clearly not a general feature in CMC patients without AIRE
mutations, whether sporadic or familial with or without hAT
(supplemental Table A). Indeed, the absence of these antibodies
in the present United Kingdom/Irish families with CMC argues
strongly against such atypical presentations of APS-I as those in
family 1.
In general, the anti-IFN antibodies in APS-I cannot be a mere
side effect ofCandida infections. They preceded the CC in every
informative case (16). Titers were also high against IFN- in all
FIG. 3. Diagnostic options for atypical or prodromal APS-I.
J Clin Endocrinol Metab, November 2008, 93(11):4389–4397 jcem.endojournals.org 4395
the 13 unusual APS-I patients who had not yet developed CC
when tested, even by ages 28–82, as in family 1 (supplemental
Table A). By contrast, antibodies to IFN-were almost negative
in some of the rare patients who developed CC late (in their 20s;
supplemental Table A), a possible hint that, when present, they
predispose toCC.Perhapsmore likely, the antibodies and theCC
may be parallel results of some shared defects upstream.
InpatientswithorwithoutAIREmutations, the immunedefects
selectively predisposing to Candida infections are unknown. Dys-
regulated cytokine production in response to Candida now seems
likelier (35) than the disordered effector T cell function invoked
initially (36) but seldom confirmed subsequently, either in vivo or
in vitro (37). Although others argue that this dysregulation is an
effect of the chronicCandida infections rather than their cause (2),
the anti-IFN antibodies might be involved indirectly, possibly by
inhibiting dendritic cell maturation and activation (44).
Genotype/phenotype/serotype correlations
Because the clinical picture in the present 15 Sardinian
patientswas broadly similar to that in Finns andNorwegians (A.
Meloni, to be published), it seems largely unaffected by environ-
mental factors or genetic background. However, there could be
biases in Italy toward thyroidautoimmunityandpossiblyagainst
insulin-dependent diabetes mellitus type 1 relative to Nordic
APS-I , even though this Sardinian population is especially sus-
ceptible to sporadic type 1 diabetes.
Not only does the present study confirm the inferred
heritability of this autoantibody response (16), but it also
extends our previous findings to patients with both additional
point substitutions and shorter truncations in the AIRE se-
quence, again regardless of the varied clinical pictures. These
antibodies co-occurred with all the disease-causingAIREmu-
tations we tested, whatever their diverse biochemical effects,
even the P252L that is the wild type in chimpanzees (38).
Figure 1 summarizes the recognizedAIREdomains. Together
with its LXXLL motifs and its two plant homeodomains, the
recently discovered caspase recruitment domain (CARD) region
at the N terminus highlights the great potential interactivity of
AIRE, e.g.with cAMP response element binding protein-binding
protein (CBP), a global trans-activator (26). The latter interac-
tionsmaybe impaired byW78RandY85C, and likely byR92W,
which are predicted toprotrude from theCARDsurface.Mutant
W78R, G228W, and R257X products are clearly synthesized
in transfected cells and retain the characteristic cytoplasmic
fibrillar staining pattern; the former two are also found in
nuclear dots, normally a correlate of trans-activation by AIRE
(7, 19, 20, 26, 28; also supplemental Refs. b–d).
Moreover, G228W has clear dominant-negative, although
quantitative, effects on coexpressedwild-typeAIREboth in vitro
(23) and in vivo in transgenic mice (39). The perfect cosegrega-
tion of these antibodies with disease manifestations and AIRE
mutations in family 1 members argues strongly that their
disorders truly are part of the APS-I spectrum and not merely
coincidental. Wild-type AIRE is known to inhibit expression
of some of its targets while enhancing that of others (39, 40).
Possibly, the contrasting rarity of AD and 100%prevalence of
hAT in family 1 might reflect such opposing effects of mutant
AIRE on thymic expression of key thyroid or adrenocortical
targets and/or on the resulting selection of effector or regu-
latory T cells. Alternatively, variant promoter sites in target
autoantigen genes (as noted in MG patients) (41) might differ
quantitatively in their sensitivity to residual wild-type AIRE.
Such Mendelian (dominant or recessive) inheritance of a
spontaneous autoantibody response is extraordinary, especially
in outbred humans (16). Its almost 100% penetrance in APS-I
patients,whatever their exactmutationor clinical picture, and its
early/persistent positivity suggest to us that it is amarker of some
common/very early event in pathogenesis before the various out-
comes diverge; these striking clues are discussed elsewhere (42).
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